Early kidney problem detection in children with sickle cell disease
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial uses special urine tests and a kidney MRI to find early signs of kidney damage in children with sickle cell disease. The goal is to detect kidney problems sooner so that treatment can start earlier and help protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The child must be younger than 18 years old.
- The child must have a confirmed sickle cell disease diagnosis, usually through a blood test.
- The child must be clinically stable — no sickle cell pain crisis, fever, or other acute illness for at least 3 weeks before the study.
- The child must not have kidney problems from other causes (like diabetes, high blood pressure, or congenital kidney issues) and must not be taking medications that harm the kidneys.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects kidney tissue samples from people with sickle cell disease and healthy volunteers to better understand how sickle cell affects the kidneys. If you have sickle cell disease or a related blood disorder, you may help researchers find new ways to protect kidney function.
This study tests two new methods to measure how well your kidneys can handle extra work, called kidney reserve. It might help find early signs of kidney problems in people with sickle cell disease or those who have donated a kidney.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
This trial tests different ways to start hydroxyurea for children with sickle cell anemia. The goal is to find the safest and most effective approach to help manage symptoms and prevent complications.
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
Hear when a new Sickle Cell Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.